Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer
Yuan Yuan, Jin Sun Lee, Susan E. Yost, et al.
European Journal of Cancer (2021) Vol. 154, pp. 11-20
Open Access | Times Cited: 59

Showing 1-25 of 59 citing articles:

Immunotherapy in breast cancer: an overview of current strategies and perspectives
Véronique Debien, Alex De Caluwé, Xiaoxiao Wang, et al.
npj Breast Cancer (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 191
The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment
Laura Morrison, Sibylle Loibl, Nicholas C. Turner
Nature Reviews Clinical Oncology (2023) Vol. 21, Iss. 2, pp. 89-105
Closed Access | Times Cited: 109
Cancer cell-intrinsic mechanisms driving acquired immune tolerance
Ehsan Ghorani, Charles Swanton, Sergio A. Quezada
Immunity (2023) Vol. 56, Iss. 10, pp. 2270-2295
Open Access | Times Cited: 50
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer
Erica L. Mayer, Yue Ren, Nikhil Wagle, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 17, pp. 2050-2060
Closed Access | Times Cited: 41
Cyclin-dependent protein kinases and cell cycle regulation in biology and disease
Ilenia Pellarin, Alessandra Dall’Acqua, Andrea Favero, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 12
CDK4: a master regulator of the cell cycle and its role in cancer
Stacey J. Baker, Poulikos I. Poulikakos, Hanna Y. Irie, et al.
Genes & Cancer (2022) Vol. 13, pp. 21-45
Open Access | Times Cited: 48
Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)
Jun Masuda, Hitomi Sakai, Junji Tsurutani, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 9, pp. e007126-e007126
Open Access | Times Cited: 34
Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer
Abhenil Mittal, Consolacion Molto Valiente, Faris Tamimi, et al.
Cancers (2023) Vol. 15, Iss. 7, pp. 2015-2015
Open Access | Times Cited: 23
Seize the engine: Emerging cell cycle targets in breast cancer
Jesús Fuentes‐Antrás, Philippe L. Bédard, David W. Cescon
Clinical and Translational Medicine (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 12
Molecular Insights on Signaling Cascades in Breast Cancer: A Comprehensive Review
Venketesh K. Panda, Barnalee Mishra, Samikshya Mahapatra, et al.
Cancers (2025) Vol. 17, Iss. 2, pp. 234-234
Open Access | Times Cited: 1
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer
Eva Valentina Klocker, Daniel Egle, Rupert Bartsch, et al.
Drugs (2025)
Open Access | Times Cited: 1
Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer
Ana C. Garrido-Castro, Noah Graham, Lestat R. Ali, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 2, pp. e010430-e010430
Open Access | Times Cited: 1
A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs
Zuzana Tatárová, Dylan C. Blumberg, James E. Korkola, et al.
Nature Biotechnology (2022) Vol. 40, Iss. 12, pp. 1823-1833
Open Access | Times Cited: 37
PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer
Lestat R. Ali, Ana C. Garrido-Castro, Patrick J. Lenehan, et al.
The Journal of Experimental Medicine (2023) Vol. 220, Iss. 4
Open Access | Times Cited: 16
Immunomodulatory effects of CDK4/6 inhibitors
Shumeng Zhang, Qiaomai Xu, Wenjia Sun, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 4, pp. 188912-188912
Closed Access | Times Cited: 16
Update on current and new potential immunotherapies in breast cancer, from bench to bedside
Emmanuelle Alaluf, Michal Mia Shalamov, Amir Sonnenblick
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
Estrogen receptor regulation of the immune microenvironment in breast cancer
Conor McGuinness, Kara L. Britt
The Journal of Steroid Biochemistry and Molecular Biology (2024) Vol. 240, pp. 106517-106517
Closed Access | Times Cited: 5
Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?
Emily J. Lelliott, Karen E. Sheppard, Grant A. McArthur
npj Precision Oncology (2022) Vol. 6, Iss. 1
Open Access | Times Cited: 22
Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer
Mónica Cejuela Solís, Andrea Vethencourt, Sònia Pernas
Current Oncology Reports (2022) Vol. 24, Iss. 12, pp. 1801-1819
Closed Access | Times Cited: 22
Post-CDK 4/6 Inhibitor Therapy: Current Agents and Novel Targets
Nadia Ashai, Sandra M. Swain
Cancers (2023) Vol. 15, Iss. 6, pp. 1855-1855
Open Access | Times Cited: 12
Deciphering the Immunomodulatory Role of Cyclin-Dependent Kinase 4/6 Inhibitors in the Tumor Microenvironment
Pratibha Pandey, Fahad Khan, Tarun Kumar Upadhyay, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2236-2236
Open Access | Times Cited: 11
CDK4/6 Inhibitor Resistance in Hormone Receptor-Positive Metastatic Breast Cancer: Translational Research, Clinical Trials, and Future Directions
Jin Sun Lee, Hannah Hackbart, Xiaojiang Cui, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11791-11791
Open Access | Times Cited: 11
CDK4/6 Inhibition Sensitizes Intracranial Tumors to PD-1 Blockade in Preclinical Models of Brain Metastasis
Naema Nayyar, Magali de Sauvage, Jane Chuprin, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 2, pp. 420-435
Open Access | Times Cited: 11
CDK4/6 Inhibitor Resistance in ER+ Breast Cancer
Ilenia Migliaccio, Cristina Guarducci, Luca Malorni
Advances in experimental medicine and biology (2025), pp. 475-493
Closed Access
Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer
James J. Asciolla, Xuewei Wu, Christos Adamopoulos, et al.
Nature Cancer (2025) Vol. 6, Iss. 1, pp. 24-40
Closed Access
Page 1 - Next Page

Scroll to top